Business Description
Minapharm Pharmaceuticals
ISIN : EGS380G1C011
Compare
Compare
Traded in other countries / regions
MIPH.Egypt IPO Date
2004-01-11Description
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.76 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.72 | |||||
Debt-to-EBITDA | 3.37 | |||||
Interest Coverage | 1.23 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.76 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.6 | |||||
3-Year EBITDA Growth Rate | 9 | |||||
3-Year EPS without NRI Growth Rate | -77.3 | |||||
3-Year FCF Growth Rate | 17.4 | |||||
3-Year Book Growth Rate | 28.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.9 | |||||
9-Day RSI | 63.79 | |||||
14-Day RSI | 61.17 | |||||
3-1 Month Momentum % | 13.91 | |||||
6-1 Month Momentum % | 82.13 | |||||
12-1 Month Momentum % | 180.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.3 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.71 | |||||
Days Inventory | 115.72 | |||||
Days Sales Outstanding | 39.41 | |||||
Days Payable | 105.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.36 | |||||
Dividend Payout Ratio | 4.24 | |||||
3-Year Dividend Growth Rate | -5.1 | |||||
Forward Dividend Yield % | 0.36 | |||||
5-Year Yield-on-Cost % | 0.36 | |||||
Shareholder Yield % | 3.77 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 35.82 | |||||
Operating Margin % | 14.29 | |||||
Net Margin % | 0.63 | |||||
EBITDA Margin % | 20.86 | |||||
FCF Margin % | -5.08 | |||||
OCF Margin % | 7.22 | |||||
ROE % | 0.79 | |||||
ROA % | 0.32 | |||||
ROIC % | 2.08 | |||||
3-Year ROIIC % | -8.15 | |||||
ROC (Joel Greenblatt) % | 14.45 | |||||
ROCE % | 11.97 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1203.59 | |||||
PE Ratio without NRI | 1183.19 | |||||
PS Ratio | 1.23 | |||||
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.44 | |||||
Price-to-Operating-Cash-Flow | 17.48 | |||||
EV-to-EBIT | 9.81 | |||||
EV-to-EBITDA | 7.03 | |||||
EV-to-Revenue | 1.47 | |||||
EV-to-FCF | -28.89 | |||||
Price-to-GF-Value | 1.93 | |||||
Price-to-Graham-Number | 8.7 | |||||
Earnings Yield (Greenblatt) % | 10.19 | |||||
FCF Yield % | -3.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Minapharm Pharmaceuticals Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil E£) | 6,438.177 | ||
| EPS (TTM) (E£) | 0.58 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.9 | ||
| 3-Year Sortino Ratio | 2.37 | ||
| Volatility % | 56.24 | ||
| 14-Day RSI | 61.17 | ||
| 14-Day ATR (E£) | 21.408177 | ||
| 20-Day SMA (E£) | 670.8445 | ||
| 12-1 Month Momentum % | 180.86 | ||
| 52-Week Range (E£) | 214.7 - 772 | ||
| Shares Outstanding (Mil) | 11.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Minapharm Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Minapharm Pharmaceuticals Stock Events
| Event | Date | Price (E£) | ||
|---|---|---|---|---|
| EGP 2.500000 Cash Dividend | 2025-08-13 | 238.38 (+0.48%) | ||
| 6.11:1 Stock Split | 2024-05-09 | 200.26 (+0.00%) |
Show
Entries
Minapharm Pharmaceuticals Frequently Asked Questions
What is Minapharm Pharmaceuticals(CAI:MIPH)'s stock price today?
The current price of CAI:MIPH is E£698.08. The 52 week high of CAI:MIPH is E£772.00 and 52 week low is E£214.70.
When is next earnings date of Minapharm Pharmaceuticals(CAI:MIPH)?
The next earnings date of Minapharm Pharmaceuticals(CAI:MIPH) is .
Does Minapharm Pharmaceuticals(CAI:MIPH) pay dividends? If so, how much?
The Dividend Yield %  of Minapharm Pharmaceuticals(CAI:MIPH) is 0.36% (As of Today), Highest Dividend Payout Ratio of Minapharm Pharmaceuticals(CAI:MIPH) was 4.24. The lowest was 0.06. And the median was 0.11. The  Forward Dividend Yield % of Minapharm Pharmaceuticals(CAI:MIPH) is 0.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane® | 2023-12-10 |
Articles on Minapharm Pharmaceuticals
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers